Iron Supplements Market

On 5 June 2023, the US Food and Drug Administration approved Injectafer, an intravenous iron sold in the United States by American Regent under licence from CSL Vifor, for iron deficiency in adults with heart failure, the first intravenous iron approved for that use. About half of people with chronic heart failure are iron deficient, and the approval turned a nutrient deficiency that cardiologists often missed into a treatment target in one of the largest chronic disease groups in the world. Douglas Insights values the iron supplements market at USD 8.36 billion in 2025 and forecasts USD 14.1 billion by 2035, a compound growth rate of 5.36%. The receipt is about 410 million people worldwide taking an iron supplement or receiving iron therapy in 2025, spending an average of USD 20.40 a year each. Users grow 3.6% a year as screening for anaemia and iron deficiency spreads in pregnancy, kidney disease, heart failure and emerging markets; spending per user grows 1.7% a year as patients who cannot tolerate tablets move to newer oral forms and intravenous iron. The report sits within Douglas Insights coverage of pharmaceuticals and follows the published Douglas Insights research methodology.

What is the iron supplements market?

The iron supplements market covers products that restore or maintain the body’s iron, about 410 million users worth USD 8.36 billion in 2025. Over-the-counter (OTC) oral iron tablets and capsules include ferrous sulphate, ferrous fumarate, ferrous gluconate and newer forms such as iron bisglycinate and polysaccharide iron, sold in pharmacies, supermarkets and online. Prescription oral iron and haematinics include iron combined with folic acid, vitamin B12 or vitamin C, and branded products such as iron polymaltose, widely prescribed in India, Europe and Latin America. Oral liquids, drops and chewables serve infants, children and people who cannot swallow tablets. Intravenous (IV) iron, including ferric carboxymaltose, iron sucrose, ferric derisomaltose and ferumoxytol, is given in hospitals, clinics and dialysis centres to people who need iron quickly or cannot absorb it by mouth. The market counts sales at manufacturer value. Iron-fortified foods, multivitamins in which iron is a minor ingredient, and blood transfusions sit outside the boundary.

How did the Injectafer heart failure approval change the iron supplements market?

The Injectafer heart failure approval opened a large new group of patients to intravenous iron, and Douglas Insights estimates heart failure patients made up about 6.5% of iron supplements value in 2025, USD 544 million, up from almost nothing before 2020. CSL Vifor’s announcement of the approval noted that about every second patient with chronic heart failure has iron deficiency, and that major cardiology guidelines in the United States and Europe recommend treating it. American Regent put the number of US adults affected by heart failure with iron deficiency or iron deficiency anaemia at about 2.8 million. Douglas Insights threads the approval through this report: it explains why intravenous iron is the fastest-growing segment, it deepens the link between CSL Vifor and its US partner, and the pace at which cardiologists test and treat iron is one of the swings in the scenarios.

Why is iron deficiency so common?

Iron deficiency is common because the body loses iron through bleeding, needs more during growth and pregnancy, and absorbs only a small share of the iron in food, and the World Health Organization estimates anaemia affects about 30% of women aged 15 to 49 worldwide. Iron deficiency causes about half of anaemia cases. It is most common in South Asia and Africa, where diets are low in absorbable iron and infections add to losses, but it also affects many women, older adults and people with chronic disease in wealthy countries. Mild iron deficiency causes tiredness and poor concentration; severe anaemia raises the risk of complications in pregnancy, slows child development and worsens heart and kidney disease.

What drives iron supplements demand to 2035?

Four drivers carry iron supplements user growth of 3.6% a year, and anaemia programmes in emerging markets are the largest. Governments in India, Africa and Southeast Asia distribute iron and folic acid tablets to pregnant women, adolescents and children, and private pharmacy sales follow as incomes rise. India’s Anaemia Mukt Bharat programme, launched in 2018, gives weekly iron and folic acid to school children and women of reproductive age. Douglas Insights values Asia Pacific iron supplements at USD 2.34 billion in 2025 and models the region growing 6.9% a year, the fastest of any region. The programme also tests for anaemia in schools and antenatal clinics, which finds millions of people who then buy iron privately.

Pregnancy and women’s health are the second driver. Most guidelines recommend iron during pregnancy, and screening for iron deficiency, not just anaemia, is spreading. Douglas Insights values iron for pregnancy and maternal health at USD 1.84 billion in 2025, 22% of the market, and estimates about 60% of pregnant women worldwide take an iron supplement at some point during pregnancy. The US Preventive Services Task Force and national bodies in Europe continue to review whether routine iron screening in pregnancy should expand, and each change in advice shifts demand quickly.

Chronic kidney disease and heart failure are the third driver. Most dialysis patients receive IV iron, and people with chronic kidney disease or heart failure who are not on dialysis are increasingly tested and treated. Douglas Insights values iron for chronic kidney disease at USD 1.17 billion in 2025 and heart failure at USD 544 million, together growing about 8% a year. Hospitals also use IV iron before planned surgery under patient blood management programmes, which cut blood transfusions and hospital stays.

New formulations are the fourth driver, measured mostly in spending per user. Many people stop taking ferrous sulphate because of stomach side effects, and gentler forms such as iron bisglycinate, sucrosomial iron and ferric maltol sell at two to ten times the price. Douglas Insights values OTC oral iron tablets and capsules at USD 2.51 billion in 2025, growing 4.0% a year, with gentler forms taking a rising share of value.

What could restrain iron supplements sales?

Three restraints remove about 0.7 points a year from iron supplements growth. Cheap generic iron is the first. Ferrous sulphate costs a few cents a day and is distributed free through public programmes, so much of the volume growth in poorer countries adds little value. Douglas Insights estimates free public supplies cover about 35% of users but only about 8% of value.

Generic competition in intravenous iron is the second restraint. Iron sucrose already faces generic competition, and generic versions of ferric carboxymaltose are arriving in Europe and other markets as patents and data protection expire. Douglas Insights assumes average IV iron prices fall about 2% a year in real terms from 2027, offset by growing use.

Side effects and safety rules are the third restraint. Oral iron often causes constipation and nausea, and many users stop early; IV iron carries a small risk of allergic reactions and, for some products, low blood phosphate. Regulators require IV iron to be given where resuscitation facilities are available, which limits use in small clinics.

Which iron supplements segments carry the value?

Intravenous iron leads the iron supplements market with 40% of 2025 value and is also the fastest-growing segment at 6.8% a year. OTC oral tablets and capsules follow at USD 2.51 billion, prescription oral iron and haematinics hold USD 1.51 billion, and oral liquids, drops and chewables USD 1.00 billion.

Intravenous iron is worth USD 3.35 billion in 2025. It leads in value although it reaches far fewer people, because one course can replace a patient’s iron in one or two visits and costs hundreds of dollars.

OTC oral tablets and capsules are worth USD 2.51 billion in 2025. They reach the most users, but low prices hold growth to 4.0% a year even as gentler forms add value.

Prescription oral iron and haematinics are worth USD 1.51 billion in 2025, carried by doctor-prescribed combinations in India, Europe and Latin America.

Oral liquids, drops and chewables are worth USD 1.00 billion in 2025, growing 5.2% a year as paediatric iron and chewable forms for adults spread.

How do indication and channel split iron supplements?

By indication, general iron deficiency and iron deficiency anaemia account for USD 3.85 billion (46%) of 2025 value, pregnancy and maternal health for USD 1.84 billion (22%), chronic kidney disease for USD 1.17 billion (14%), heart failure for USD 544 million (6.5%), and general wellness and other uses for USD 962 million (11.5%). By channel, pharmacies account for USD 3.60 billion (43%), hospitals and clinics for USD 2.59 billion (31%), online stores for USD 1.13 billion (13.5%) and supermarkets and mass retail for USD 1.05 billion (12.5%).

Why is intravenous iron taking share from tablets?

Intravenous iron is taking share from tablets because it works faster and avoids the stomach side effects that make many people stop oral iron, and Douglas Insights estimates IV iron’s share of iron supplements value rises from 40% in 2025 to about 46% by 2035. Newer IV irons such as ferric carboxymaltose and ferric derisomaltose can give a full dose of 1,000 mg or more in one or two short infusions, where older products needed five or more visits. Hospitals use IV iron before surgery to reduce blood transfusions, obstetricians use it for severe anaemia late in pregnancy, and cardiologists now use it in heart failure. The limits are cost, the need for a clinic visit and safety monitoring, so oral iron remains the first choice for most mild deficiency.

How do public anaemia programmes shape iron supplements?

Public anaemia programmes shape iron supplements by putting free tablets in the hands of hundreds of millions of people, and Douglas Insights estimates they reach about 140 million users a year, about 35% of all users, while accounting for about 8% of market value. Governments buy iron and folic acid tablets through low-price tenders, usually from local generic makers, and distribute them through schools, health workers and antenatal clinics. These programmes raise awareness, and when people are diagnosed as anaemic, many go on to buy branded or gentler iron at pharmacies. For suppliers, public tenders are a volume business with thin margins, while the private market that grows around them carries the value. Programme funding, supply gaps and changes in national guidelines are the main risks.

Which regions buy the most iron supplements?

North America buys 33% of iron supplements by value, USD 2.76 billion in 2025, while Asia Pacific grows fastest at 6.9% a year. The United States leads in IV iron use for kidney disease, heart failure and surgery, and has a large OTC supplement market. The region grows 4.5% a year.

Europe buys USD 2.26 billion and grows 4.2% a year. Europe was the first market for ferric carboxymaltose and has high IV iron use, but generic entry and price controls slow value growth.

Asia Pacific buys USD 2.34 billion and grows 6.9% a year, the fastest rate, led by India’s large haematinics market and national anaemia programmes, and by China and Southeast Asia. Latin America buys USD 502 million and grows 6.0%. The Middle East is the wildcard at USD 293 million and 6.4% a year, where anaemia rates among women remain high. Africa buys USD 209 million and grows 6.8%, with most supply through public health programmes.

Who are the leading iron supplements companies?

Douglas Insights estimates that the three largest iron supplements companies hold about 25% of 2025 value, all built on intravenous iron, while oral iron is split among thousands of brands.

Advantage in iron supplements rests on clinical evidence in intravenous iron and on brand and distribution in oral iron. CSL Vifor built ferric carboxymaltose into a global franchise through trials in heart failure, kidney disease and surgery; American Regent sells it in the United States; Pharmacosmos competes with a one-visit high-dose product. In oral iron, supplement brands such as Nature Made, Feroglobin and Floradix compete on gentleness and trust, while Indian makers dominate the country’s large prescription haematinics market.

How are iron supplements priced?

Iron supplement users spent an average of USD 20.40 a year in 2025, and Douglas Insights expects about USD 24.10 by 2035. A month of generic ferrous sulphate costs USD 1 to USD 5, a month of gentler OTC iron such as bisglycinate USD 8 to USD 25, and a month of branded prescription haematinics in India about USD 2 to USD 6. A course of branded intravenous iron in the United States can cost USD 1,000 to USD 3,000 including administration, and USD 200 to USD 800 in Europe, while generic iron sucrose costs much less. Most users take oral iron for two to six months, so average annual spending stays low even as IV iron lifts value.

Which rules apply to iron supplements?

Iron supplements fall under two sets of rules: OTC oral iron is regulated as a dietary or food supplement in the United States and the EU, with limits on dose and labelling, while prescription oral iron and all intravenous iron are regulated as medicines needing approval from the FDA, the European Medicines Agency or national regulators. US rules require a child-poisoning warning on iron supplements, because accidental overdose was once a leading cause of poisoning deaths in young children. India regulates iron supplements under FSSAI nutraceutical rules and prescription iron under drug law, and public programmes set national dosing.

How far could iron supplements reach under each scenario?

The base scenario takes the iron supplements market to USD 14.1 billion by 2035, with a range of USD 11.5 billion to USD 17.0 billion. The base case combines 3.6% user growth with 1.7% spending growth for 5.36% a year. The slower scenario assumes public programmes stall, generic IV iron cuts prices faster and cardiologists adopt iron treatment slowly, setting the legs at 2.4% and 0.8% for USD 11.5 billion. The faster scenario assumes wider screening for iron deficiency and faster growth in IV iron, setting the legs at 4.6% and 2.6% for USD 17.0 billion. Each 1-point change in user growth moves the 2035 figure by about USD 1.42 billion.

Douglas Exclusive: the iron therapy switching tracker

The iron therapy switching tracker records, for 30 countries, the share of iron patients on oral and intravenous iron by indication, guideline changes, generic IV iron launches and public programme coverage, so suppliers can see where patients are moving between products. Related markets are covered in the Nutraceutical Products Market, Dialysis Equipment Market and Health Self Monitoring Technologies Market reports.

Methodology and receipts

The iron supplements model is built bottom-up from users. The headline receipt is about 410 million users multiplied by USD 20.40 of annual spending, giving USD 8.36 billion for 2025. Users are estimated for 30 countries from anaemia prevalence, pregnancy, kidney disease and heart failure data, treatment rates and public programme coverage, and spending from product prices and treatment lengths, reconciled with company revenue. The forecast compounds 3.6% user growth and 1.7% spending growth from the 2025 base to about 584 million users and USD 14.1 billion in 2035.

Sources

1. CSL Limited (CSL Vifor) Injectafer approved in the U.S. for the treatment of iron deficiency in patients with heart failure (2023)
2. American Regent, Inc. INJECTAFER approved in the U.S. for the treatment of iron deficiency in adult patients with heart failure (2023)
3. World Health Organization WHO Global Health Observatory: noncommunicable disease indicators (2026)